ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a further preclinical model of pulmonary arterial hypertension (PAH). NTP42 targets a novel pathway in PAH, namely the thromboxane receptor (TP) signaling axis. In this seminal study, NTP42 used in mono-therapy or, in line with current treatment guidelines, in combination with other existing PAH drug therapies, has the potential to attenuate multiple key PAH disease features and